Biostatistics and Mathematical Oncology Core Shared Resource ABSTRACT The Biostatistics and Mathematical Oncology Core (BMOC) provides City of Hope Comprehensive Cancer Center (COHCCC) members with access to expert statisticians and mathematicians who collaborate in basic, translational, clinical, and population research. The BMOC staff assist in the development of experimental designs, sample size estimation, statistical computing, data analysis, and interpretation of findings. In collaboration with investigators, they contribute to COHCCC publications and are a resource for new statistical methods in laboratory-based, clinical trial-based, and population-based research. Areas of expertise include: clinical trials; dose-escalation methods; survival analysis; cure models; preclinical studies, assays, bioassays, and toxicity screening; experimental and human genetics; gene expression (e.g., RNA-seq, microarray, NanoString), classification, prediction and signatures; 16s rRNA microbiome taxonomy; longitudinal and functional data analysis; mathematical modeling of cancer; extracting data from 3-dimensional tumor images; epidemiology and observational studies; adaptive questionnaires; SEER, TCGA, and other public databases; and extensive experience in statistics applied to cancer research involving immunology, cellular, and immune- directed therapy, and hematopoietic stem-cell transplantation. The BMOC is directed by Jeffrey Longmate, Ph.D., and draws upon the efforts of 20 faculty and staff who provide a wide range of expertise and play diverse roles in COHCCC research. Major changes have been made to the BMOC since the last review, including the recruitment of Russell Rockne, PhD, to lead a new mathematical oncology service line; the addition of Andrei Rodin, PhD, the Dr. Susumo Ohno Chair in Theoretical Biology; and the recruitment of two statisticians to support the Hematologic Malignancies Program. Operational changes include the appointment of statisticians to Disease Teams and major changes in statistical review procedures for the Protocol Review and Monitoring System. The primary goal of the Core is collaboration, development, and advancement of novel methods in the design, conduct, analysis, and publication of preclinical and clinical cancer-related research. The BMOC provides free short-term consulting to promote early statistical input. During the last finding period, BMOC faculty developed and published novel study designs and data analysis methods, which have been incorporated into Phase I and I/II clinical trials. The BMOC is supported by the Office of Shared Resources and overseen by the BMOC Advisory Committee, which includes the COHCCC Program Leaders. BMOC members work closely with the Integrative Genomics and Bioinformatics Core and the Analytical Pharmacology Core. In the last year, the BMOC supported 401 projects from 117 investigators, including 89 CC members, 48 of whom have peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059199
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications